Polypid Ltd (PYPD)

Dec 20, 2024

FY2024 Earnings Estimate for PolyPid Issued By HC Wainwright - Defense World

Dec 20, 2024

Dec 17, 2024

PolyPid (NASDAQ:PYPD) Given “Buy” Rating at HC Wainwright - Defense World

Dec 17, 2024

Dec 17, 2024

Critical Survey: PAVmed (NASDAQ:PAVM) and PolyPid (NASDAQ:PYPD) - Defense World

Dec 17, 2024

Dec 13, 2024

PolyPid announces collaboration with ImmunoGenesis in solid tumors - The Cancer Letter

Dec 13, 2024

Dec 13, 2024

PolyPid Ltd. Announces Research and Development Collaboration with ImmunoGenesis, Inc. Leveraging PLEX Technology to Enhance Cancer Immunotherapy - Marketscreener.com

Dec 13, 2024

Dec 12, 2024

PolyPid announces research, development collaboration with ImmunoGenesis - Yahoo Finance

Dec 12, 2024

Dec 12, 2024

PolyPid enters R&D pact with ImmunoGenesis By Investing.com - Investing.com South Africa

Dec 12, 2024

Dec 11, 2024

PolyPid stock hits 52-week low at $2.81 amid market challenges - Investing.com

Dec 11, 2024

Dec 11, 2024

PolyPid enters R&D pact with ImmunoGenesis - Investing.com India

Dec 11, 2024

Dec 11, 2024

PolyPid Collaborates with ImmunoGenesis to Boost Cancer Immunotherapy - TipRanks

Dec 11, 2024

Dec 11, 2024

PolyPid Announces Research and Development Collaboration - GlobeNewswire

Dec 11, 2024

Dec 11, 2024

PolyPid Announces Research and Development Collaboration with ImmunoGenesis Leveraging PLEX Technology to Enhance Cancer Immunotherapy - Yahoo Finance

Dec 11, 2024

Dec 11, 2024

PolyPid Partners with ImmunoGenesis to Revolutionize Cancer Immunotherapy Drug Delivery - StockTitan

Dec 11, 2024

Dec 05, 2024

PolyPid stock touches 52-week low at $2.93 amid market challenges - Investing.com Nigeria

Dec 05, 2024

Nov 29, 2024

PolyPid Faces Nasdaq Non-Compliance Challenge - TipRanks

Nov 29, 2024

Nov 29, 2024

PolyPid Announces Receipt of Nasdaq Notification of Minimum Stockholders’ Equity Non-Compliance - GlobeNewswire

Nov 29, 2024

Nov 29, 2024

PolyPid Faces Nasdaq Non-Compliance, Pivotal Trial Results Due December | PYPD Stock News - StockTitan

Nov 29, 2024

Nov 14, 2024

PolyPid Ltd. (NASDAQ:PYPD) Q3 2024 Earnings Call Transcript - Insider Monkey

Nov 14, 2024

Nov 14, 2024

PolyPid Ltd. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2024 - Marketscreener.com

Nov 14, 2024

Nov 14, 2024

PolyPid Ltd (PYPD) Q3 2024 Earnings Call Highlights: Strategic Advances Amid Financial Challenges By GuruFocus - Investing.com Canada

Nov 14, 2024

Nov 13, 2024

PolyPid Reports Q3 Results Amid SHIELD II Trial Progress - TipRanks

Nov 13, 2024

Nov 13, 2024

PolyPid Announces SHIELD II Trial Progress and Financials - TipRanks

Nov 13, 2024

Nov 13, 2024

PolyPid Provides Corporate Update and Reports Third Quarter 2024 Financial Results - GlobeNewswire

Nov 13, 2024

Nov 12, 2024

PolyPid (PYPD) to Release Earnings on Wednesday - Defense World

Nov 12, 2024

Nov 08, 2024

PolyPid Announces $8.25 Million Share Sale Plan - TipRanks

Nov 08, 2024

Nov 07, 2024

PYPDPolyPid Ltd. Ordinary Shares Latest Stock News & Market Updates - StockTitan

Nov 07, 2024

Nov 07, 2024

PolyPid to Participate in the Craig-Hallum 15th Annual Alpha Select Conference - StockTitan

Nov 07, 2024

Nov 05, 2024

Craig-Hallum Initiates Coverage of PolyPid (PYPD) with Buy Recommendation - MSN

Nov 05, 2024

Nov 05, 2024

PolyPid shares rise on strong Phase 3 prospects, gets buy rating - Investing.com Canada

Nov 05, 2024

Oct 30, 2024

PolyPid to Report Third Quarter 2024 Financial Results and Operational Highlights on November 13, 2024 - GlobeNewswire

Oct 30, 2024

Oct 28, 2024

Will PolyPid Wield The SHIELD? - RTTNews

Oct 28, 2024

Oct 23, 2024

Rosalind Advisors, Inc. Reduces Stake in PolyPid Ltd - GuruFocus.com

Oct 23, 2024

Oct 21, 2024

PolyPid Announces Publication in International Journal of - GlobeNewswire

Oct 21, 2024

Oct 21, 2024

PolyPid Announces Publication in International Journal of Surgery Highlighting Results of Phase 3 SHIELD I Trial of D-PLEX₁₀₀ in Prevention of Surgical Site Infections in Abdominal Colorectal Surgery - StockTitan

Oct 21, 2024

Oct 02, 2024

PolyPid retains stock target, buy rating on positive trial enrollment update By Investing.com - Investing.com South Africa

Oct 02, 2024

Oct 02, 2024

PolyPid retains stock target, buy rating on positive trial enrollment update - Investing.com India

Oct 02, 2024

Oct 01, 2024

PolyPid completes enrollment for phase 3 trial - Investing.com

Oct 01, 2024

Oct 01, 2024

PolyPid Nears Completion of Key Phase 3 Trial - TipRanks

Oct 01, 2024

Oct 01, 2024

PolyPid Announces Last Patient In for Planned Unblinded - GlobeNewswire

Oct 01, 2024

Oct 01, 2024

PolyPid Announces Last Patient In for Planned Unblinded Interim Analysis in the Ongoing SHIELD II Phase 3 Trial Evaluating D-PLEX₁₀₀ for the Prevention of Abdominal Colorectal Surgical Site Infections - StockTitan

Oct 01, 2024

Sep 03, 2024

PolyPid to Participate in Three Upcoming Fall Investor Conferences - GlobeNewswire

Sep 03, 2024

Aug 19, 2024

Equities Analysts Offer Predictions for PolyPid Ltd.’s Q3 2024 Earnings (NASDAQ:PYPD) - Defense World

Aug 19, 2024

Aug 17, 2024

HC Wainwright Reiterates “Buy” Rating for PolyPid (NASDAQ:PYPD) - Defense World

Aug 17, 2024